Compare EARN & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EARN | QTRX |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.8M | 160.0M |
| IPO Year | 2012 | 2017 |
| Metric | EARN | QTRX |
|---|---|---|
| Price | $4.27 | $3.19 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | $5.38 | ★ $6.00 |
| AVG Volume (30 Days) | 351.3K | ★ 835.8K |
| Earning Date | 06-16-2026 | 05-06-2026 |
| Dividend Yield | ★ 20.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $37,632,000.00 |
| Revenue This Year | $7.69 | $25.49 |
| Revenue Next Year | $19.57 | $10.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 64.52 |
| 52 Week Low | $4.10 | $2.15 |
| 52 Week High | $5.73 | $8.77 |
| Indicator | EARN | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.47 | 57.03 |
| Support Level | N/A | $2.89 |
| Resistance Level | $4.49 | $3.25 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 49.84 | 92.68 |
Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.